A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.

Journal Article (Journal Article)

Ovarian cancer accounts for more deaths than all other gynecological cancers combined. To identify common low-penetrance ovarian cancer susceptibility genes, we conducted a genome-wide association study of 507,094 SNPs in 1,768 individuals with ovarian cancer (cases) and 2,354 controls, with follow up of 21,955 SNPs in 4,162 cases and 4,810 controls, leading to the identification of a confirmed susceptibility locus at 9p22 (in BNC2). Here, we report on nine additional candidate loci (defined as having P ≤ 10⁻⁴) identified after stratifying cases by histology, which we genotyped in an additional 4,353 cases and 6,021 controls. We confirmed two new susceptibility loci with P ≤ 5 × 10⁻⁸ (8q24, P = 8.0 × 10⁻¹⁵ and 2q31, P = 3.8 × 10⁻¹⁴) and identified two additional loci that approached genome-wide significance (3q25, P = 7.1 × 10⁻⁸ and 17q21, P = 1.4 × 10⁻⁷). The associations of these loci with serous ovarian cancer were generally stronger than with other cancer subtypes. Analysis of HOXD1, MYC, TIPARP and SKAP1 at these loci and of BNC2 at 9p22 supports a functional role for these genes in ovarian cancer development.

Full Text

Duke Authors

Cited Authors

  • Goode, EL; Chenevix-Trench, G; Song, H; Ramus, SJ; Notaridou, M; Lawrenson, K; Widschwendter, M; Vierkant, RA; Larson, MC; Kjaer, SK; Birrer, MJ; Berchuck, A; Schildkraut, J; Tomlinson, I; Kiemeney, LA; Cook, LS; Gronwald, J; Garcia-Closas, M; Gore, ME; Campbell, I; Whittemore, AS; Sutphen, R; Phelan, C; Anton-Culver, H; Pearce, CL; Lambrechts, D; Rossing, MA; Chang-Claude, J; Moysich, KB; Goodman, MT; Dörk, T; Nevanlinna, H; Ness, RB; Rafnar, T; Hogdall, C; Hogdall, E; Fridley, BL; Cunningham, JM; Sieh, W; McGuire, V; Godwin, AK; Cramer, DW; Hernandez, D; Levine, D; Lu, K; Iversen, ES; Palmieri, RT; Houlston, R; van Altena, AM; Aben, KKH; Massuger, LFAG; Brooks-Wilson, A; Kelemen, LE; Le, ND; Jakubowska, A; Lubinski, J; Medrek, K; Stafford, A; Easton, DF; Tyrer, J; Bolton, KL; Harrington, P; Eccles, D; Chen, A; Molina, AN; Davila, BN; Arango, H; Tsai, Y-Y; Chen, Z; Risch, HA; McLaughlin, J; Narod, SA; Ziogas, A; Brewster, W; Gentry-Maharaj, A; Menon, U; Wu, AH; Stram, DO; Pike, MC; Wellcome Trust Case-Control Consortium, ; Beesley, J; Webb, PM; Australian Cancer Study (Ovarian Cancer), ; Australian Ovarian Cancer Study Group, ; Ovarian Cancer Association Consortium (OCAC), ; Chen, X; Ekici, AB; Thiel, FC; Beckmann, MW; Yang, H; Wentzensen, N; Lissowska, J; Fasching, PA; Despierre, E; Amant, F; Vergote, I; Doherty, J; Hein, R; Wang-Gohrke, S; Lurie, G; Carney, ME; Thompson, PJ; Runnebaum, I; Hillemanns, P; Dürst, M; Antonenkova, N; Bogdanova, N; Leminen, A; Butzow, R; Heikkinen, T; Stefansson, K; Sulem, P; Besenbacher, S; Sellers, TA; Gayther, SA; Pharoah, PDP; Ovarian Cancer Association Consortium (OCAC),

Published Date

  • October 2010

Published In

Volume / Issue

  • 42 / 10

Start / End Page

  • 874 - 879

PubMed ID

  • 20852632

Pubmed Central ID

  • PMC3020231

Electronic International Standard Serial Number (EISSN)

  • 1546-1718

Digital Object Identifier (DOI)

  • 10.1038/ng.668


  • eng

Conference Location

  • United States